Drug intelligence / Profile preview

Kanglaibao

Development stage: Preclinical
Lead developer: Beijing University of Chinese Medicine
Modality: Small Molecules
Administration: Oral

Overview

Kanglaibao is a preparation described as "food grade non-jian granules" (fried-free granules) that is currently undergoing clinical study. It is being investigated for its use in the treatment of children with gastrointestinal heat accumulation and for the prevention of respiratory tract infection. The clinical study is being run by Beijing University of Chinese Medicine and Key deployment projects of the Chinese Academy of Sciences.

Brand names: Kanglaibao
Other names: food grade non-jian granules免煎颗粒

Beyond the preview

Go deeper on Kanglaibao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kanglaibao.

Explore the full profile